11.49

3.33% 0.37

Pre-market: 11.47 -0.02 -0.17%

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $11.49, with a volume of 268.34K. It is up +3.33% in the last 24 hours and down -1.71% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$11.12

Open:

$11.14

24h Volume:

268.34K

Relative Volume:

0.67

Market Cap:

$227.36M

Revenue:

$244.06M

Net Income/Loss:

$87.01M

P/E Ratio:

6.3087

EPS:

1.8213

Net Cash Flow:

$105.95M

1W Performance:

-0.17%

1M Performance:

-1.71%

6M Performance:

-24.51%

1Y Performance:

-21.14%

1-Day Range:

$11.14

$11.58

1-Week Range:

$10.88

$11.69

52-Week Range:

$10.41

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	11.49	227.36M	244.06M	87.01M	105.95M	1.8213
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

May 02, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat

May 02, 2026

May 01, 2026

KROS stock: Does the Takeda deal lower dilution risk in 2026? - MSN

May 01, 2026

Apr 29, 2026

Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc - Barchart

Apr 29, 2026

Apr 28, 2026

Keros Therapeutics (KROS) Business Update | Q4 2025: Earnings UnderperformShared Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026

Apr 22, 2026

[ARS] Keros Therapeutics, Inc. SEC Filing - Stock Titan

Apr 22, 2026

Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return - Stock Titan

Apr 22, 2026

KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 22, 2026

KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 22, 2026

Apr 20, 2026

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - The Globe and Mail

Apr 20, 2026

KROS Rinvatercept: What to Know Before DMD Phase II Starts - Barchart

Apr 20, 2026

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView

Apr 20, 2026

Keros Therapeutics (KROS) Stock: Growth vs Risks (Momentum Fading) 2026-04-20Verified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 18, 2026

Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 By Investing.com - Investing.com India

Apr 18, 2026

Apr 17, 2026

Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS) - GuruFocus

Apr 17, 2026

Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 - Investing.com

Apr 17, 2026

Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock - MarketBeat

Apr 17, 2026

[Form 4] Keros Therapeutics, Inc. Insider Trading Activity - Stock Titan

Apr 17, 2026